Cargando…
Lung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas genome correction in cystic fibrosis models
Approximately 10% of Cystic Fibrosis (CF) patients, particularly those with CF transmembrane conductance regulator (CFTR) gene nonsense mutations, lack effective treatments. The potential of gene correction therapy through delivery of the CRISPR/Cas system to CF-relevant organs/cells is hindered by...
Autores principales: | Wei, Tuo, Sun, Yehui, Cheng, Qiang, Chatterjee, Sumanta, Traylor, Zachary, Johnson, Lindsay T., Coquelin, Melissa L., Wang, Jialu, Torres, Michael J., Lian, Xizhen, Wang, Xu, Xiao, Yufen, Hodges, Craig A., Siegwart, Daniel J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640563/ https://www.ncbi.nlm.nih.gov/pubmed/37951948 http://dx.doi.org/10.1038/s41467-023-42948-2 |
Ejemplares similares
-
Selective ORgan Targeting (SORT) nanoparticles for tissue specific mRNA delivery and CRISPR/Cas gene editing
por: Cheng, Qiang, et al.
Publicado: (2020) -
Membrane destabilizing ionizable phospholipids for organ selective mRNA delivery and CRISPR/Cas gene editing
por: Liu, Shuai, et al.
Publicado: (2021) -
Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing
por: Wei, Tuo, et al.
Publicado: (2020) -
siRNA Functionalized Lipid Nanoparticles (LNPs) in Management of Diseases
por: Kalita, Tutu, et al.
Publicado: (2022) -
Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy
por: Zhang, Di, et al.
Publicado: (2022)